Dr. Kogan and his team at GWCIM offer most of the ReCODE program (The Dr. Bredesen protocol™ and the ReCODE Protocol™ ) for Alzheimer treatment via TeleHealth to new and existing patients.
However, starting in May 2023 we may require ReCODE program patients from non-DMV area to present for initial visit in person at our office downtown Washington, DC.
Submit New Patient Inquiry FormAbout Alzheimer’s Disease (AD)
Alzheimer’s Disease (AD) is the most expensive and morbid disease of our time. The most recent report by the Alzheimer’s Association points out that if we don’t change the current trend, one in three older adults will die from AD. Most experts do not accept that AD can’t be cured by a single approach or medication, even though an effective AD-modified metabolic approach already exists. Over 200 medications have been tried and failed as curative AD targets.
GWCIM experience with AD
Since 2008, Dr. Kogan has been applying a functional medicine approach to control underlying metabolic disruptors present in patients with AD. By 2015 GWCIM team had successfully slowed down and reversed AD progression in several patients and began to develop methodological approaches to serving patients with this debilitating disease. In 2017, Dr Kogan and his team members took one of the first courses taught by the ReCODE developer Dr. Dale Bredesen (https://www.apollohealthco.com/dr-bredesen/) and received certification in the ReCODE program. Since becoming Bredesen’s certified practice, they have demonstrated many successful cases of AD reversal; several cases were
published in peer-reviewed journals. For example: https://pubmed.ncbi.nlm.nih.gov/32951747/
At GWCIM we have treated over 60 patients utilizing ReCODE. Our program has been reviewed by GW University IRB and designated a “clinical program” that does not require formal IRB approval. Our team has completed ReCODE2 training. The age of our patients is a bit older than average in other ReCODE-certified clinics because we do not restrict entry into our program. We have seen patients even with very advanced AD arrest progression. Our current statistics show that about a third of patients improve, a quarter progress, and for the rest, we are observing an arrest of progression and clinical stability. At this point, some patients have been followed for over 5 years.
We highly recommend reading Dr. Bredesen books where he explains all details of his approach: https://www.apollohealthco.com/dr-bredesen/#publications
We also invite you to listen to GW Integrative medicine podcast with Dr. Bredesen hosted by Dr Kogan:
Listen to Podcast
GWCIM ReCODE Program
We encourage ALL interested patients to schedule a brief 30min consultation with Dr Kogan to outline the ReCODE program and design an individual personal implementation plan.
GWCIM team providing care for patients on Bredesen’s protocol:
- Dr Kogan, MD – GWCIM ReCODE Medical Director
- Ajowa Ifateyo, Program Coordinator and Health Coach
- Sally Novak, LCSW, DOM, L.Ac., MSW – Psychotherapy, Support Groups
- Mold assessment and remediation expert (Dr. Mikhail Sogonov)
- Mind Body and Movement teachers (Mara Brenner and Yael Flusberg)
- Bioidentical Hormone’s expert (Marianna Ledenac)
- Supplement Manager (Monica Arias)
- Functional lab coordinator (Hannah Fine)
We strongly advise all interested patients to join Apollo Health ReCode program ReCODE Protocol – Preventing Cognitive Decline And Alzheimer’s, that provides community support, ReCode reports, cognitive training, access to advanced cognitive testing and much more.
The program outline
1. Starts with comprehensive 2.5 hr intake with dr. Kogan at which point all tests will be organized to assess for all key AD drivers. These tests may include but not limited to: comprehensive cognitive assessment, brain imaging, blood work, and number of functional medicine tests.
2. Continues with 90 min follow up visits in approximately 4-8 weeks or when we have all test results.
3. Patients who have previously purchased a ReCODE report should schedule an initial 90min intake visit to start the work immediately. However, it is possible that additional tests will be needed depending on what AD drivers have been uncovered.
4. We recommend genetic testing either immediately at the onset of working together or soon after. Patients have a number of options for genetic testing but we recommend most comprehensive through InteLLxxDNA which provides the most comprehensive detailed information.
Cost of the ReCODE program
Often the cost of dental work determines most of the cost of the first-year treatment. We use a wide referral network of trusted dental providers, and we do not partner with any specific dental practice to avoid conflict of interest.
All visits are billed as a fee for service and are highly personalized. ReCODE program visits are not covered by any insurance policies. The fees will be discussed with each patient due to the complexity of this program. Please visit the “Fees, Cancelations, Insurance Page” describing GWCIM policies.
We are partnered with Greenspring Financial Services, a “Daily Money Management Services”, who’s mission is easing the burden of managing daily financial obligations for the families of people with cognitive decline.
Partnering with GWU Memory Clinic
The GWCIM ReCODE program is NOT a substitution for your Neurologist or Memory doctor. If you don’t have one or would like to work with a GWCIM affiliated program we would be happy to refer you to GWU Memory Clinic. Our patients benefit from GWCIM and GWU Memory Clinic’s close partnership, which includes holding regular clinical meetings and exchanging medical records. In contrast to GWCIM, GWU Memory Clinic accepts most insurances.
Before scheduling the initial visit: please inquire directly at (202) 741-2870 to confirm that your insurance is accepted by GWU Memory Clinic
In addition, we partner closely with the GW Speech and Hearing Program and GW Occupational Therapy programs.
GWCIM is a separate business entity from all organizations mentioned in this overview
While GWCIM is closely affiliated with GW University and Medical Faculty Associates (GW MFA), and Dr Kogan is a full-time Associate Professor of Medicine at GW MFA, GWCIM is operating as a separate business.
GWCIM ReCODE-related Research
- 1. GWCIM ReCODE Program Assessment project with over 60 patients in the program. Publishing of the data is projected for 2023
- Partnered with GW Office of Integrative Medicine to attract additional funds to improve assessment and bring low-income patients into the program. Prospective donors: please, contact GW Office of Integrative Medicine
- 2. AlzLife Light Therapy research.
- In 2020 GWCIM has been approved to begin the first open label trial of 40Hz Light Therapy for patients with early form of AD and Minimal Cognitive Impairment. We are currently publishing findings of our study.
- 3. Microbiome assessment and modification as part of treatment of MCI and early AD.
- We are clinical site of recently funded ground breaking study of assessing effects of microbiome optimization on MCI and early AD. Interested patients can contact GW Office of Integrative Medicine
- 4. Cannabinoids for AD assessment program. *** Please note that Cannabis is a Schedule 1 DEA-controlled substance and is currently reported to not have any proven medical use. Given a large amount of preclinical data on neuroprotective and anti-neuro-inflammatory effects, we have started assessing the effects of different cannabinoids on patients with AD. At present, we have collected data on dozens of patients and are ready to start a controlled trial for patients in Maryland and DC. We discuss all observed and recorded effects with most of GWCIM ReCODE patients.
Cannabinoid therapies
If you are currently not a GWCIM patient and wish to receive counseling on this topic, please schedule a 30min consultation with Dr Kogan to discuss cannabinoid therapies.
To our prospective allies and donors:
If you are a prospective donor and interested in supporting this initiative please don’t hesitate to contact GWCIM. GWCIM welcomes additional clinical trial opportunities and encourages interested patients, donors, and organizations to contact us with questions and suggestions.
